FIELD: medicine.
SUBSTANCE: group of inventions refers to treating neurological behaviour development disorders, including attention deficit syndrome (ADS), attention deficit/hyperactivity syndrome (ADHS). A therapeutic agent presented in the form of a pharmaceutical composition containing an activated-potentiated form of antibodies to the brain-specific S-100 protein, and an activated-potentiated form of antibodies to endothelial NO-synthase as an additional exalting component is administered.
EFFECT: effective treatment of the above pathology by the synergetic neurotropic action of the components of the therapeutic agent.
14 cl, 2 ex, 4 tbl, 1 dwg
